[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573819":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":29,"responsibleParty":218,"collaborators":21,"id":220,"slug":221,"hasResults":222,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":21,"eligibilityCriteria":226,"healthyVolunteers":222,"sex":227,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":21,"studyType":233,"phases":234,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":32,"whyStopped":21,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Secukinumab","EXPERIMENTAL","Secukinumab administered intravenously in pediatric participants with JPsA",[13],"Biological: Secukinumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Intravenous secukinumab",[9],[20],"AIN457",null,[23,28],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":24,"role":25,"phone":21,"phoneExt":21,"email":21},[30,52,68,85,101,118,135,151,168,185,201],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Loma Linda University Health","RECRUITING","Loma Linda","California","92354","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-117.26115,34.04835,{"lat":42,"lon":41},[45,49],{"name":46,"role":25,"phone":47,"phoneExt":21,"email":48},"Monica Pizana","+1 909 558 5830","mpizana@llu.edu",{"name":50,"role":51,"phone":21,"phoneExt":21,"email":21},"Wendy De La Pena","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":32,"city":54,"state":55,"zip":56,"country":36,"countryCode":37,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University of Florida","Gainesville","Florida","32610 8068",{"type":39,"coordinates":58},[59,60],-82.32483,29.65163,{"lat":60,"lon":59},[63,66],{"name":64,"role":25,"phone":21,"phoneExt":21,"email":65},"Joel Ravel","Joal.Ravel@UFHelath.ORG",{"name":67,"role":51,"phone":21,"phoneExt":21,"email":21},"Christian Oliveros",{"facility":69,"status":32,"city":70,"state":71,"zip":72,"country":36,"countryCode":37,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Ann and Robert H Lurie Childs Hosp","Chicago","Illinois","60611",{"type":39,"coordinates":74},[75,76],-87.65005,41.85003,{"lat":76,"lon":75},[79,83],{"name":80,"role":25,"phone":81,"phoneExt":21,"email":82},"Tyler Sorensen","+1 312 227 4811","tsorensen@luriechildrens.org",{"name":84,"role":51,"phone":21,"phoneExt":21,"email":21},"Pooja Patel",{"facility":86,"status":32,"city":87,"state":87,"zip":88,"country":36,"countryCode":37,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Col Uni Med Center New York Presby","New York","10032",{"type":39,"coordinates":90},[91,92],-74.00597,40.71427,{"lat":92,"lon":91},[95,99],{"name":96,"role":25,"phone":97,"phoneExt":21,"email":98},"Marcela Arizabaleta","+1 646 317 1669","ma5005@cumc.columbia.edu",{"name":100,"role":51,"phone":21,"phoneExt":21,"email":21},"Lisa Imundo",{"facility":102,"status":32,"city":103,"state":104,"zip":105,"country":36,"countryCode":37,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Levine Childrens Hospital","Charlotte","North Carolina","28203",{"type":39,"coordinates":107},[108,109],-80.84313,35.22709,{"lat":109,"lon":108},[112,116],{"name":113,"role":25,"phone":114,"phoneExt":21,"email":115},"Haley D Furr","+1 800 821 1535","Haley.Furr@advocatehealth.org",{"name":117,"role":51,"phone":21,"phoneExt":21,"email":21},"Sheetal Vora",{"facility":119,"status":32,"city":120,"state":121,"zip":122,"country":36,"countryCode":37,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Cincinnati Childrens Hospital","Cincinnati","Ohio","45229",{"type":39,"coordinates":124},[125,126],-84.51439,39.12711,{"lat":126,"lon":125},[129,133],{"name":130,"role":25,"phone":131,"phoneExt":21,"email":132},"Megan Quinlan-Waters","+1 513 636 7261","Megan.Quinlan-Waters@cchmc.org",{"name":134,"role":51,"phone":21,"phoneExt":21,"email":21},"Hermine Brunner",{"facility":136,"status":32,"city":137,"state":121,"zip":138,"country":36,"countryCode":37,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Univ Hosp Cleveland Medical Center","Cleveland","44106-5028",{"type":39,"coordinates":140},[141,142],-81.69541,41.4995,{"lat":142,"lon":141},[145,149],{"name":146,"role":25,"phone":147,"phoneExt":21,"email":148},"Katrina Gogin","+1 216 844 7164","katrina.gogin@uhhospitals.org",{"name":150,"role":51,"phone":21,"phoneExt":21,"email":21},"Ezequiel Borgia",{"facility":152,"status":32,"city":153,"state":154,"zip":155,"country":36,"countryCode":37,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Legacy Emanuel Research Hosp Portland","Portland","Oregon","97232",{"type":39,"coordinates":157},[158,159],-122.67621,45.52345,{"lat":159,"lon":158},[162,166],{"name":163,"role":25,"phone":164,"phoneExt":21,"email":165},"Brenna Bogle","+1 503 413 5447","bbogle@lhs.org",{"name":167,"role":51,"phone":21,"phoneExt":21,"email":21},"Daniel Joseph Kingsbury",{"facility":169,"status":32,"city":170,"state":171,"zip":172,"country":36,"countryCode":37,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Childrens Hosp Pittsburgh UPMC","Pittsburgh","Pennsylvania","15224",{"type":39,"coordinates":174},[175,176],-79.99589,40.44062,{"lat":176,"lon":175},[179,183],{"name":180,"role":25,"phone":181,"phoneExt":21,"email":182},"Vibha Chauhan","+1 412 692 6327","vibha.chauhan@chp.edu",{"name":184,"role":51,"phone":21,"phoneExt":21,"email":21},"Margalit Rosenkranz",{"facility":186,"status":32,"city":187,"state":188,"zip":189,"country":36,"countryCode":37,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Texas Arthritis Center","El Paso","Texas","79902",{"type":39,"coordinates":191},[192,193],-106.48693,31.75872,{"lat":193,"lon":192},[196,199],{"name":197,"role":25,"phone":21,"phoneExt":21,"email":198},"Melissa Lopez","melissa.lopez@aara.care",{"name":200,"role":51,"phone":21,"phoneExt":21,"email":21},"Sanjay Chabra",{"facility":202,"status":32,"city":203,"state":204,"zip":205,"country":36,"countryCode":37,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"University of Utah","Salt Lake City","Utah","84113",{"type":39,"coordinates":207},[208,209],-111.89105,40.76078,{"lat":209,"lon":208},[212,216],{"name":213,"role":25,"phone":214,"phoneExt":21,"email":215},"Tressie Rollins","+1 415 515 8212","tressie.rollins@hsc.utah.edu",{"name":217,"role":51,"phone":21,"phoneExt":21,"email":21},"Peter Chiraseveenuprapund",{"type":219,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100573819","phase-1-study-to-evaluate-the-pharmacokinetics-pk-safety-and-tolerability-up-to-6-years-of-intravenous-iv-secukinumab-in-pediatric-participants-with-juvenile-psoriatic-arthritis-jpsa-100573819",false,"NCT06751238","Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).","An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis","Key Inclusion Criteria:\n\n* Participants parent's or legal representative(s) written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the participant reaches age of consent (as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form).\n* Males and females ≥2 years old to \\\u003C18 years old at the time of screening.\n* Confirmed diagnosis of JPsA according to the modified International League of Associations for Rheumatology (ILAR) classification criteria that must have occurred at least 6 months prior to screening.\n* Active JPsA disease defined as ≥3 active joints (swollen or if not swollen must be both tender and limited range of motion) at baseline (BSL).\n* Inadequate response (≥1 month) or intolerance to ≥1 Non-Steroidal Anti-Inflammatory Drug (NSAID) at screening.\n* Inadequate response (≥2 months) or intolerance to ≥ 1 Disease Modifying Anti-Rheumatic Drug (DMARD) at screening.\n* Concomitant use of the following second-line agents such as disease-modifying and\u002For immunosuppressive drugs to treat the JPsA will be allowed:\n\n  * Stable dose of methotrexate (MTX) (maximum of 20 mg\u002F m2 BSA\u002F week) for at least 4 weeks prior to the BSL visit, with folic\u002Ffolinic acid supplementation (according to standard medical practice of the center).\n  * Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of \\\u003C0.2 mg\u002Fkg\u002Fday or up to 10 mg\u002Fday maximum, whichever is less, for at least 7 days prior to BSL.\n  * Stable dose of no more than one NSAID for at least 1 week prior to BSL.\n\nKey Exclusion Criteria:\n\n* Participants with body weight less than 10 kg at screening.\n* Use of other investigational drugs within 4 weeks or 5 half-lives of BSL, or until the expected pharmacodynamic effect has returned to BSL, whichever is longer.\n* History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes.\n* Participants with active inflammatory bowel disease or active uveitis at screening or BSL.\n* Fulfilling diagnostic criteria for any International League of Associations for Rheumatology (ILAR ) juvenile idiopathic arthritis (JIA) category other than JPsA at BSL.\n* Participants treated with prohibited medication\n* Participants taking any non-biologic DMARD at screening except for MTX.\n* Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.\n\nOther inclusion\u002Fexclusion criteria may apply","ALL","2 Years","17 Years",{"count":231,"type":232},20,"ESTIMATED","INTERVENTIONAL",[235],"PHASE1","The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA",[238],"Juvenile Psoriatic Arthritis",[240,241,242,243,244,9],"Pediatric","JPsA","Pharmacokinetic (PK)","safety","Intravenous (i.v.)","2026-08-20",{"date":247,"type":248},"2026-08-21","ACTUAL",{"date":250,"type":248},"2025-09-24",{"date":252,"type":232},"2031-03-11",{"name":24,"class":6},11]